Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial
We conducted a study to assess the effect of rosuvastatin use on fibrinolysis in patients with previous venous thromboembolism (VTE). This was a post hoc analysis within the STAtins Reduce Thrombophilia (START) study (NCT01613794). Plasma fibrinolytic potential, fibrinogen, plasmin inhibitor, plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) were measured before and after four weeks of rosuvastatin or no treatment in participants with prior confirmed VTE, after ending anticoagulant therapy. In the non-rosuvastatin group (n = 121), plasma fibrinolytic potential and individual fibrinolysis parameters did not change at the end of the study versus the baseline, whereas in the rosuvastatin group (n = 126), plasma fibrinolytic potential increased: the mean clot lysis time decreased by 8·75 min (95% CI −13·8 to −3·72), and plasmin inhibitor levels and TAFI activity were lower at the end of the study (−0·05 U/ml; 95% CI −0·07 to −0·02 and −4·77%; 95% CI −6·81 to −2·73, respectively). PAI-1 levels did not change and fibrinogen levels were 0·17 g/l (95% CI 0·04–0·29) higher. In participants with prior VTE, rosuvastatin use led to an increased fibrinolytic potential compared with non-statin use. Our findings support the need for further studies on the possible role for statins in the secondary prevention of VTE.
|blood coagulation tests, fibrin clot lysis time, fibrinolysis, HMG-CoA reductase inhibitors, venous thromboembolism|
|British Journal of Haematology|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Schol-Gelok, S, de Maat, M.P.M, Biedermann, J.S, van Gelder, T, Leebeek, F.W.G, Lijfering, W.M, … Kruip, M.J.H.A. (2020). Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. British Journal of Haematology. doi:10.1111/bjh.16648